Lamivudine/Nevirapine/Stavudine

拉米夫定/奈韦拉平/司他夫定

Report date: 2023/04/21 16:05:17

Base Information

Drug NameLamivudine/Nevirapine/Stavudine

Drug Alias Name奈韦拉平司他拉米双夫定Lamivudine, Nevirapine, And Stavudinestavudine, lamivudine and nevirapineLamivudine, Stavudine and NevirapineStavudine/lamivudine/nevirapine +[7]

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues

Mechanisms of ActionReverse transcriptase inhibitorsHuman immunodeficiency virus type 1 reverse transcriptase inhibitors

TargetsHuman immunodeficiency virus type 1 reverse transcriptaseReverse transcriptase

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes Nevirapine Stavudine Lamivudine

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesJiangsu Xipula Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Xipula Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsHIV Infections

Inactive IndicationsN/A

Other Information

ATC CodeJ05AR07